Plaque Psoriasis Gets a New Treatment Option in India

Plaque psoriasis patients in India may soon have a new treatment option. Optimus Pharma has received approval from the Drug Controller General of India (DCGI). The approval covers Tapinarof Cream 1% w/w for adult patients with plaque psoriasis.

The approval allows Optimus Pharma to manufacture and market the topical medicine in India. The company is among the first Indian firms to receive regulatory approval for this product.

Optimus Pharma gets DCGI approval for Tapinarof

Tapinarof is a non-steroidal topical treatment used for plaque psoriasis. It belongs to a newer class of topical medicines called aryl hydrocarbon receptor agonists. The cream is designed for application directly to affected areas of the skin. Its non-steroidal profile may offer another choice for adults managing plaque psoriasis.

According to the company, the DCGI approval marks an important step in bringing the treatment to Indian patients.

Key details include:

• Drug: Tapinarof Cream 1% w/w
• Indication: Plaque psoriasis
• Patient group: Adults
• Route: Topical application
• Regulatory approval: DCGI, India
• Company: Optimus Pharma

What the new psoriasis treatment means for patients

Plaque psoriasis is a chronic skin condition that causes raised, inflamed, and scaly patches. It can affect different parts of the body. Treatment depends on the severity and location of the condition. Topical medicines are commonly used for patients with mild to moderate psoriasis.

Tapinarof offers a non-steroidal approach. This can be relevant for patients who need long-term management options. The treatment works by activating the aryl hydrocarbon receptor. This pathway plays a role in regulating immune responses and skin barrier function.

The approval could also expand access to newer topical psoriasis medications in India. It gives doctors another option when considering treatment plans for eligible adult patients.

Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market

Optimus Pharma expands its dermatology portfolio

The DCGI nod strengthens Optimus Pharma's presence in the dermatology segment. The company has been expanding its pharmaceutical portfolio across several therapeutic areas. The approval also comes as demand for effective chronic skin disease treatments continues to grow.

For patients, the availability of a new topical medicine could provide greater choice. However, treatment decisions should depend on a doctor's assessment. The company will now focus on manufacturing and marketing the approved product in India. Further availability will depend on its commercial launch plans and distribution.

Key takeaways

• Optimus Pharma has received DCGI approval for Tapinarof Cream 1%.
• The medicine is indicated for adults with plaque psoriasis.
• Tapinarof is a non-steroidal topical treatment.
• The approval allows Optimus Pharma to manufacture and market the product.
• The move adds another treatment option for plaque psoriasis patients in India.